Krystal Biotech, Inc. (NASDAQ:KRYS) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) have been assigned a consensus recommendation of “Moderate Buy” from the twelve research firms that are currently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and ten have given a buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $324.1111.

A number of research analysts recently weighed in on the stock. Guggenheim raised their target price on shares of Krystal Biotech from $224.00 to $284.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. Weiss Ratings raised shares of Krystal Biotech from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Thursday, April 9th. Wall Street Zen raised shares of Krystal Biotech from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Jefferies Financial Group raised their target price on shares of Krystal Biotech from $310.00 to $371.00 and gave the company a “buy” rating in a research report on Tuesday, February 17th. Finally, Citigroup lifted their price objective on shares of Krystal Biotech from $371.00 to $378.00 and gave the company a “buy” rating in a research report on Tuesday, May 5th.

Krystal Biotech Stock Performance

KRYS opened at $302.05 on Friday. The firm’s fifty day moving average is $270.39 and its two-hundred day moving average is $256.01. The firm has a market cap of $8.90 billion, a PE ratio of 40.38 and a beta of 0.50. Krystal Biotech has a twelve month low of $122.80 and a twelve month high of $319.48.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, May 4th. The company reported $1.83 earnings per share for the quarter, topping the consensus estimate of $1.45 by $0.38. Krystal Biotech had a net margin of 53.92% and a return on equity of 19.25%. The company had revenue of $116.36 million for the quarter, compared to analyst estimates of $112.11 million. Equities analysts forecast that Krystal Biotech will post 7.98 EPS for the current fiscal year.

Insider Transactions at Krystal Biotech

In other news, Director Daniel Janney sold 37,895 shares of the firm’s stock in a transaction dated Tuesday, February 24th. The shares were sold at an average price of $266.88, for a total transaction of $10,113,417.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Kathryn Romano sold 750 shares of Krystal Biotech stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $267.60, for a total transaction of $200,700.00. Following the completion of the sale, the chief accounting officer owned 22,366 shares of the company’s stock, valued at $5,985,141.60. This trade represents a 3.24% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 97,714 shares of company stock worth $26,183,109 in the last ninety days. Insiders own 13.10% of the company’s stock.

Hedge Funds Weigh In On Krystal Biotech

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bessemer Group Inc. lifted its holdings in shares of Krystal Biotech by 106.9% during the 3rd quarter. Bessemer Group Inc. now owns 149 shares of the company’s stock worth $26,000 after acquiring an additional 77 shares during the period. Sound Income Strategies LLC lifted its holdings in shares of Krystal Biotech by 1,270.0% during the 4th quarter. Sound Income Strategies LLC now owns 137 shares of the company’s stock worth $34,000 after acquiring an additional 127 shares during the period. Western Wealth Management LLC acquired a new position in Krystal Biotech during the 1st quarter worth approximately $34,000. Greenline Wealth Management LLC acquired a new position in Krystal Biotech during the 4th quarter worth approximately $34,000. Finally, Danske Bank A S acquired a new position in Krystal Biotech during the 3rd quarter worth approximately $35,000. 86.29% of the stock is owned by institutional investors and hedge funds.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.